Indian Patent Office Disallows Patent for Boehringer Ingelheim’s HIV Drug, Nevirapine - 21.10.2015

Indian Patent Office has disallowed Germany's Boehringer Ingelheim a patent on its HIV drug, Nevirapine, sold as Viramune XR (extended release), yet again thwarting attempts by Big Pharma for "exclusivity" extension on their patented drugs to reportedly block entry of affordable generics.

Tags : Boehringer Ingelheim Patent HIV Drug Nevirapine

Share :